Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries
Tack, Jan (Katholieke Universiteit te Leuven (1970-))
Stanghellini, Vincenzo (University Hospital S.Orsola)
Mearin, Fermín 1956- (Centro Médico Teknon)
Yiannakou, Yan (County Durham and Darlington NHS Trust)
Layer, Peter (Israelitic Hospital)
Coffin, Benoit (Paris Diderot University)
Simren, Magnus (Sahlgrenska University Hospital (Suècia))
Mackinnon, Jonathan (TFS Develop S.L)
Wiseman, Gwen (Allergan International)
Marciniak, Anne (Allergan International)
Brotons, Carlos (Institut d'Investigació Biomèdica Sant Pau)
Universitat Autònoma de Barcelona

Fecha:	2019
Resumen:	Irritable bowel syndrome with predominant constipation (IBS-C) is a complex disorder with gastrointestinal and nervous system components. The study aim was to assess the economic burden of moderate to severe IBS-C in six European countries (France, Germany, Italy, Spain, Sweden and the UK). An observational, one year retrospective-prospective (6 months each) study of patients diagnosed in the last five years with IBS-C (Rome III criteria) and moderate to severe disease at inclusion (IBS Symptom Severity Scale score ≥ 175). The primary objective was to assess the direct cost to European healthcare systems. Five hundred twenty-five patients were included, 60% (range: 43. 1-78. 8%) suffered from severe IBS-C. During follow-up 11. 1-24. 0% of patients had a hospitalisation/emergency room (ER) visit, median stay range: 1. 5-12. 0 days and 41. 1-90. 4% took prescription drugs for IBS-C. 21. 4-50. 8% of employed patients took sick leave (mean: 11. 6-64. 1 days). The mean annual direct cost to the healthcare systems was €937. 1- €2108. 0. The total direct cost (combined costs to healthcare systems and patient) for IBS-C was €1421. 7-€2487. 1. IBS-C is not a life-threatening condition; however, it has large impact on healthcare systems and society. Direct and indirect costs for moderate to severe IBS-C were high with the largest direct cost driver being hospitalisations/ER visits.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Economic Analysis ; Europe ; Healthcare resource utilisation ; IBS ; IBS-C
Publicado en:	BMC Gastroenterology, Vol. 19 Núm. 1 (july 2019) , p. 69, ISSN 1471-230X

DOI: 10.1186/s12876-019-0985-1
PMID: 31064345

13 p, 965.1 KB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados